BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| rifaximin - environmental samples |
👶
Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach Clinical and Experimental Gastroenterology (Clin Exp Gastroenterol ) Vol: 8 Issue Pages: 309-325 Pub: 2015 Dec 4 Epub: 2015 Dec 4 Authors Soldi S , Vasileiadis S , Uggeri F , Campanale M , Morelli L , Fogli MV , Calanni F , Grimaldi M , Gasbarrini A , Publication Publication |
| rifaximin - environmental samples |
👶
Rifaximin modulates the colonic microbiota of patients with Crohn`s disease: an in vitro approach using a continuous culture colonic model system. The Journal of antimicrobial chemotherapy (J Antimicrob Chemother ) Vol: 65 Issue 12 Pages: 2556-65 Pub: 2010 Dec Epub: 2010 Sep 18 Authors Maccaferri S , Vitali B , Klinder A , Kolida S , Ndagijimana M , Laghi L , Calanni F , Brigidi P , Gibson GR , Costabile A , Publication Publication |
| rifaximin - environmental samples |
👶
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. Beneficial microbes (Benef Microbes ) Vol: 11 Issue 6 Pages: 519-525 Pub: 2020 Oct 12 Epub: 2020 Sep 4 Authors Ponziani FR , Scaldaferri F , De Siena M , Mangiola F , Matteo MV , Pecere S , Petito V , Sterbini FP , Lopetuso LR , Masucci L , Cammarota G , Sanguinetti M , Gasbarrini A , Publication Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
